Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ChiCTR2600120718 Tapinarof Psoriasis of scalp Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
ChiCTR2600120718 clinical trial report covering Tapinarof, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07478003 Methylprednisolone ST Elevation Myocardial Infarction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07478003 clinical trial report covering Methylprednisolone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07478822 Recombinant Botulinum Toxin Type A (Claruvis) Upper limb spasticity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07478822 clinical trial report covering Recombinant Botulinum Toxin Type A (Claruvis), Phase 3, endpoints, sponsor, geography, readout timing and develo
Latest Hotspot
8 min read
IRCT20260226068952N1 Reteplase Hemodialysis complication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
IRCT20260226068952N1 clinical trial report covering Reteplase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07479784 Octreotide Acetate Pancreatic Fistula Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07479784 clinical trial report covering Octreotide Acetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07479615 Comekibart Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07479615 clinical trial report covering Comekibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07479797 KITE-753 Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07479797 clinical trial report covering KITE-753, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07480356 TARA-002 Non-Muscle Invasive Bladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07480356 clinical trial report covering TARA-002, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07479043 Mesenchymal stem cells (Therapeutic Solutions International) Respiratory Distress Syndrome, Acute Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07479043 clinical trial report covering Mesenchymal stem cells (Therapeutic Solutions International), Phase 3, endpoints, sponsor, geography, readout ti
Latest Hotspot
8 min read
NCT07481799 Becotatug vedotin Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07481799 clinical trial report covering Becotatug vedotin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07483736 Amoxicillin/Clavulanate Potassium Chemotherapy-Induced Febrile Neutropenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07483736 clinical trial report covering Amoxicillin/Clavulanate Potassium, Phase 3, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07482085 Efavirenz Creutzfeldt-Jakob Disease, Sporadic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07482085 clinical trial report covering Efavirenz, Phase 3, endpoints, sponsor, geography, readout timing and development white space.